AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25153084 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily non-nucleoside reverse transcriptase inhibitor/nucleoside reverse transcriptase inhibitor (NNRTI/NRTI) regimen (EFV+FTC/TDF)
Number of subjects: 1571
Study 25153084 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily NNRTI/NRTI regimen (EFV+3TC/ZDV)
Number of subjects: 1571
Study 25153084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill-count non-adherence
Number of subjects: 1571
Study 25153084 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report non-adherence
Number of subjects: 1571
Study 22149319 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 150
Study 22149319 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 150
Study 22149319 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 *3/*3 variant
Number of subjects: 150
Study 19319182 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied to the anterior temporal lobes throughout the encoding and retrieval stages
Number of subjects: 0
Study 19319182 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stimulation (anodal left/cathodal right anterior temporal lobe stimulation)
Number of subjects: 0
Study 19319182 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral stimulation (anodal left ATL stimulation with a large contralateral cathodal electrode)
Number of subjects: 0
Study 19319182 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 17401619 — intervention group
Group type: EXPERIMENTAL
Intervention: IOLMaster measurements
Number of subjects: 95
Study 15180172 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative treatment with Otovowen (fixed combination of plant‐based tinctures and homeopathic potencies)
Number of subjects: 390
Study 15180172 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (free combinations of decongestant nose drops, mucolytics, analgesics and antibiotics)
Number of subjects: 390
Study 15180172 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative treatment with Otovowen
Number of subjects: 390
Study 15180172 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 390
Study 11467436 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegic induction (group T)
Number of subjects: 28
Study 11467436 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegic induction (group C)
Number of subjects: 28
Study 9570261 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole treatment strategy (10 mg stepping up to 20 mg and 40 mg as required)
Number of subjects: 725
Study 9570261 — intervention group
Group type: COMPARATOR
Intervention: Antacid-alginate/ranitidine treatment strategy (10 mL q.d.s. stepping up to ranitidine 150 mg b.d. and 150 mg q.d.s. as required)
Number of subjects: 725
Study 7774326 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate and vitamin B12
Number of subjects: 38
Study 7774326 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 38
Study 3078803 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines
Number of subjects: 4
Study 3078803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31024112 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs with funding statements
Number of subjects: 0
Study 31024112 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs with intervention description
Number of subjects: 0
Study 31024112 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of IRB statements
Number of subjects: 0
Study 31024112 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding and allocation concealment
Number of subjects: 0
Study 31024112 — intervention group
Group type: EXPERIMENTAL
Intervention: Jadad scores
Number of subjects: 0
Study 31246083 — intervention group
Group type: EXPERIMENTAL
Intervention: Decayed, Missing and Filled Teeth (DMFT/dmtf) index
Number of subjects: 530
Study 31246083 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental Aesthetic Index (DAI)
Number of subjects: 530
Study 28659128 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation plus minimally invasive esophagectomy (MIE)
Number of subjects: 264
Study 28659128 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy plus minimally invasive esophagectomy (MIE)
Number of subjects: 264
Study 28659128 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation plus MIE
Number of subjects: 264
Study 28659128 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy plus MIE
Number of subjects: 264
Study 26125194 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous fascia iliaca compartment block (FIB)
Number of subjects: 51
Study 26125194 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA) using fentanyl
Number of subjects: 51
Study 23813280 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month multimodal training
Number of subjects: 117
Study 23813280 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 117
Study 20510611 — intervention group
Group type: EXPERIMENTAL
Intervention: Static air overlay mattress on top of a cold foam mattress
Number of subjects: 83
Study 20510611 — intervention group
Group type: COMPARATOR
Intervention: Cold foam mattress alone
Number of subjects: 83
Study 19016274 — intervention group
Group type: EXPERIMENTAL
Intervention: Division of short gastric vessels (group 1)
Number of subjects: 99
Study 19016274 — intervention group
Group type: COMPARATOR
Intervention: Intact short gastric vessels (group 2)
Number of subjects: 99
Study 19016274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study 16771939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (250 mg)
Number of subjects: 100
Study 16771939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 14607452 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1041
Study 14607452 — intervention group
Group type: COMPARATOR
Intervention: TEE-guided treatment
Number of subjects: 1041
Study 14607452 — intervention group
Group type: COMPARATOR
Intervention: No spontaneous conversion (No-SC)
Number of subjects: 1041
Study 10997674 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 0
Study 10997674 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition (PN)
Number of subjects: 0
Study 10997674 — intervention group
Group type: COMPARATOR
Intervention: No Parenteral Nutrition (no PN)
Number of subjects: 0
Study 8737165 — intervention group
Group type: EXPERIMENTAL
Intervention: Water available on the dining table
Number of subjects: 0
Study 8737165 — intervention group
Group type: COMPARATOR
Intervention: Water available 20 feet from the table
Number of subjects: 0
Study 8737165 — intervention group
Group type: COMPARATOR
Intervention: Water available 40 feet from the table
Number of subjects: 0
Study 8737165 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing effort to obtain water
Number of subjects: 0
Study 8737165 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a social model
Number of subjects: 0
Study 8737165 — intervention group
Group type: EXPERIMENTAL
Intervention: Social and economic factors interaction
Number of subjects: 0
Study 1483291 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg
Number of subjects: 28
Study 1483291 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 1.2 mg
Number of subjects: 28
Study 1483291 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (Control)
Number of subjects: 28
Study 2932138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 80 micrograms
Number of subjects: 9
Study 2932138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 200 micrograms
Number of subjects: 9
Study 2932138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 400 micrograms
Number of subjects: 9
Study 30736479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum PS128 supplementation
Number of subjects: 0
Study 30290769 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care (ANC) clinic attendance
Number of subjects: 1719
Study 30290769 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV status check
Number of subjects: 1719
Study 30290769 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin level check
Number of subjects: 1719
Study 30290769 — intervention group
Group type: EXPERIMENTAL
Intervention: Syphilis screening
Number of subjects: 1719
Study 30290769 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid vaccination
Number of subjects: 1719
Study 30290769 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimalarial drugs
Number of subjects: 1719
Study 30290769 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihelminthic drugs
Number of subjects: 1719
Study 30290769 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements
Number of subjects: 1719
Study 27338180 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn cohort
Number of subjects: 30997
Study 27338180 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn cohort (children <18 years)
Number of subjects: 30997
Study 27338180 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn cohort (adults ≥18 years)
Number of subjects: 30997
Study 24997307 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy/continuous smokers
Number of subjects: 0
Study 24997307 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional smokers
Number of subjects: 0
Study 24997307 — intervention group
Group type: COMPARATOR
Intervention: Quitters/decreasers
Number of subjects: 0
Study 24997307 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 0
Study 22572911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1152
Study 22572911 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1152
Study 20683355 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 18
Study 20683355 — intervention group
Group type: COMPARATOR
Intervention: No stretching
Number of subjects: 18
Study 18727948 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day)
Number of subjects: 30
Study 18727948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16840580 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+MCFA-rich oil emulsion after the 2-wk MCFA-rich dietary condition (MC-MC)
Number of subjects: 9
Study 16840580 — intervention group
Group type: COMPARATOR
Intervention: CHO+MCFA-rich oil emulsion after one of the LCFA-rich dietary conditions (LC-MC)
Number of subjects: 9
Study 16840580 — intervention group
Group type: COMPARATOR
Intervention: CHO only following a LCFA-rich diet (LC-CHO)
Number of subjects: 9
Study 12505955 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet with 0.5 mL of lidocaine 1%
Number of subjects: 400
Study 12505955 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet with 0.5 mL of lidocaine 2%
Number of subjects: 400
Study 12505955 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 400
Study 12505955 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet with 0.5 mL of saline
Number of subjects: 400
Study 12505955 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet with lidocaine 1%
Number of subjects: 400
Study 12505955 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet with lidocaine 2%
Number of subjects: 400
Study 11783225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM)
Number of subjects: 55
Study 11783225 — intervention group
Group type: COMPARATOR
Intervention: Amino acid (Control)
Number of subjects: 55
Study 7751490 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support treatment
Number of subjects: 137
Study 7751490 — intervention group
Group type: COMPARATOR
Intervention: Self-control treatment
Number of subjects: 137
Study 10171156 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedicus vortex pump (Group B)
Number of subjects: 16
Study 10171156 — intervention group
Group type: COMPARATOR
Intervention: Stockert roller pump (Group S)
Number of subjects: 16
Study 367884 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam 20 mg
Number of subjects: 18
Study 367884 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam 5 mg
Number of subjects: 18
Study 367884 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam 10 mg
Number of subjects: 18
Study 31889322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus daclatasvir (Gp 1)
Number of subjects: 107
Study 31889322 — intervention group
Group type: COMPARATOR
Intervention: Ombitasvir, paritaprevir and ritonavir plus ribavirin (Gp 2)
Number of subjects: 107
Study 31152588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0
Study 31152588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29086025 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulotomy
Number of subjects: 64
Study 29086025 — intervention group
Group type: COMPARATOR
Intervention: Non-capsulotomy (Control)
Number of subjects: 64
Study 25972490 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 1.5 mg three times daily for 3 weeks
Number of subjects: 50
Study 25972490 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times daily for 3 weeks
Number of subjects: 50
Study 25972490 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 1.5 mg
Number of subjects: 50
Study 25972490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23279569 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS of the right primary motor cortex (M1)
Number of subjects: 18
Study 23279569 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS of the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 18
Study 23279569 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 18
Study 21675867 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmydriatic retinal imaging and discussion of retinal findings
Number of subjects: 113
Study 21675867 — intervention group
Group type: COMPARATOR
Intervention: Standard endocrinology evaluation alone
Number of subjects: 113
Study 18264836 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal liposuction (AL)
Number of subjects: 20
Study 16408462 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0
Study 16408462 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihyperglycemic agent treatment
Number of subjects: 0
Study 16408462 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 12570112 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort) 160/4.5 microg
Number of subjects: 812
Study 12570112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 812
Study 12570112 — intervention group
Group type: COMPARATOR
Intervention: Formoterol 4.5 microg
Number of subjects: 812
Study 12570112 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 200 microg
Number of subjects: 812
Study 12690774 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions designed by the researcher plus routine hospital instructions
Number of subjects: 60
Study 12690774 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital instructions only
Number of subjects: 60
Study 9739438 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU 425 mg/m2 given by bolus injection on days 1‐5 plus intravenous (i.v.) LV 20 mg/m2 every four to five weeks
Number of subjects: 306
Study 9739438 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU 3.5 g/m2/week in a 48‐hour continuous infusion
Number of subjects: 306
Study 7994260 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) administration during and after autologous bone marrow transplantation (BMT)
Number of subjects: 10
Study 7994260 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan and cyclophosphamide conditioning regimen prior to BMT
Number of subjects: 10
Study 7994260 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured marrow cells infused on day 0 after 8 days of culture with IL-2
Number of subjects: 10
Study 2920496 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (250 mg) with Ferrous sulfate (325 mg)
Number of subjects: 8
Study 2920496 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (250 mg) without Ferrous sulfate (325 mg)
Number of subjects: 8
Study 7402678 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning signal before noxious stimuli (45-51°C)
Number of subjects: 7
Study 7402678 — intervention group
Group type: COMPARATOR
Intervention: No warning signal before noxious stimuli (45-51°C)
Number of subjects: 7
Study 7402678 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect-result responses
Number of subjects: 7
Study 7402678 — intervention group
Group type: COMPARATOR
Intervention: Affect-process responses
Number of subjects: 7
Study 31103505 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand Massage
Number of subjects: 60
Study 31103505 — intervention group
Group type: COMPARATOR
Intervention: Hand Holding
Number of subjects: 60
Study 31103505 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 60
Study 29459019 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (rtCGM)
Number of subjects: 149
Study 29459019 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-monitoring of blood glucose)
Number of subjects: 149
Study 27697278 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P: Positive Parenting Program (8 weeks of group online participation)
Number of subjects: 12
Study 27697278 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 12
Study 25065293 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-D chemotherapy
Number of subjects: 830
Study 25065293 — intervention group
Group type: COMPARATOR
Intervention: Standard anthracycline-based chemotherapy
Number of subjects: 830
Study 25065293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 830
Study 23229693 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate office-based nasolacrimal duct probing
Number of subjects: 163
Study 23229693 — intervention group
Group type: COMPARATOR
Intervention: Observation/nonsurgical management followed by deferred facility probing
Number of subjects: 163
Study 18692279 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced model of clinical placement for final year nursing students (trial participants)
Number of subjects: 92
Study 18692279 — intervention group
Group type: COMPARATOR
Intervention: Non-trial participants (control group)
Number of subjects: 92
Study 17990386 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated percutaneous discectomy
Number of subjects: 0
Study 17990386 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser discectomy
Number of subjects: 0
Study 17990386 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency denervation
Number of subjects: 0
Study 15724823 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening (experimental group)
Number of subjects: 0
Study 15724823 — intervention group
Group type: COMPARATOR
Intervention: Non-listening (control group)
Number of subjects: 0
Study 16579083 — intervention group
Group type: EXPERIMENTAL
Intervention: No. 2 Qu Feng Shi Ling capsules and Fenbid
Number of subjects: 82
Study 16579083 — intervention group
Group type: COMPARATOR
Intervention: Lei Gong Teng Tablets and Fenbid
Number of subjects: 82
Study 9534837 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention about tardive dyskinesia
Number of subjects: 56
Study 9534837 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 56
Study 9534837 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 7655378 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (4800-6000 mg/m2) and carboplatin (1200-1800 mg/m2) followed by autologous bone marrow or peripheral blood stem cell infusion
Number of subjects: 43
Study 7655378 — intervention group
Group type: COMPARATOR
Intervention: High-dose cyclophosphamide and carboplatin regimen
Number of subjects: 43
Study 2541168 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(4) PFU of D x RRV reassortant
Number of subjects: 116
Study 2541168 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(4) PFU of DS1 x RRV reassortant
Number of subjects: 116
Study 2541168 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(4) PFU of RRV
Number of subjects: 116
Study 2541168 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 10(3) PFU of D x RRV and 5 x 10(3) PFU of RRV
Number of subjects: 116
Study 2541168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 1213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 58
Study 1213 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 58
Study 31582408 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (ILS)
Number of subjects: 2015
Study 31582408 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 2015
Study 31582408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 2015
Study 26727045 — intervention group
Group type: EXPERIMENTAL
Intervention: RFCA
Number of subjects: 237
Study 26727045 — intervention group
Group type: EXPERIMENTAL
Intervention: CRYO
Number of subjects: 237
Study 26727045 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBINED
Number of subjects: 237
Study 23564922 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide 1 (GLP-1) infusion
Number of subjects: 0
Study 23564922 — intervention group
Group type: COMPARATOR
Intervention: Acute hyperglycemia
Number of subjects: 0
Study 23564922 — intervention group
Group type: COMPARATOR
Intervention: Acute hypoglycemia
Number of subjects: 0
Study 21864370 — intervention group
Group type: EXPERIMENTAL
Intervention: PEPS therapy plus treatment as usual (TAU)
Number of subjects: 340